Truqap Side Effects Linked to Discontinuation Risks, FDA Staffers Warn

Summary

FDA drug experts warned a panel of scientific advisors that Truqap’s toxicity has been linked to a high number of treatment discontinuations, as the manufacturer seeks approval to expand use of the breast cancer drug for prostate cancer.